Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Treatment-naïve, Genotype 1 Hepatitis C infected Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms QUEST-1
- Sponsors Janssen R&D Ireland
- 14 Jul 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
- 20 May 2015 Results of pooled data from ADVANCE, QUEST 1 and 2 trials comparing efficacy of simeprevir and telaprevir presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 10 Oct 2014 A post-hoc analysis of pooled efficacy data from QUEST 1 and 2 was presented at the Viral Hepatitis Congress (VHC).